Valuation : GSK plc

Market Cap 74.21B 101B 86.56B 81.04B 140B 9,631B 140B 960B 375B 4,854B 379B 370B 16,065B P/E 2026 *
14x
P/E 2027 * 11.5x
Enterprise Value 94.05B 128B 110B 103B 177B 12,206B 178B 1,216B 475B 6,152B 480B 469B 20,360B EV / Sales 2026 *
2.77x
EV / Sales 2027 * 2.57x
Free-Float
92.75%
Yield 2026 *
3.76%
Yield 2027 * 4.05%
1 day+0.40%
1 week-3.27%
Current month-3.58%
1 month-6.58%
3 months-2.04%
6 months-13.20%
Current year+2.71%
1 week 21.49
Extreme 21.49
22.37
1 month 21.1
Extreme 21.1
23.61
Current year 20.27
Extreme 20.27
26.02
1 year 16.55
Extreme 16.55
26.02
3 years 14.68
Extreme 14.675
26.02
5 years 14.62
Extreme 14.62
27.13
10 years 14.62
Extreme 14.62
27.52
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%-3.27% - - 101B
-0.26%-6.53%+60.31%+111.83% 1,048B
+0.04%-1.39%+51.88%+62.20% 640B
-0.48%-2.92%+23.71%+74.47% 456B
-1.50%-4.34%+37.66%+38.65% 362B
-0.72%-2.83%+21.94%+36.88% 295B
-0.81%-0.18%+1.32%+11.33% 255B
-0.88%-1.27%+51.86%+69.07% 236B
+0.03%-1.99%-17.82%-54.39% 204B
-1.56%+0.57%+30.55%+90.75% 185B
Average -0.57%-0.72%+29.05%+48.98% 409.07B
Weighted average by Cap. -0.49%-1.92%+38.56%+65.41%

Financials

2026 *2027 *
Net sales 33.94B 46.12B 39.59B 37.06B 63.93B 4,404B 64.11B 439B 172B 2,220B 173B 169B 7,347B 35.52B 48.26B 41.43B 38.79B 66.9B 4,609B 67.09B 459B 180B 2,323B 181B 177B 7,688B
Net income 5.44B 7.39B 6.34B 5.94B 10.24B 705B 10.27B 70.29B 27.48B 356B 27.73B 27.13B 1,177B 6.48B 8.81B 7.56B 7.08B 12.22B 842B 12.25B 83.85B 32.78B 424B 33.08B 32.37B 1,404B
Net Debt 19.84B 26.96B 23.14B 21.67B 37.37B 2,575B 37.48B 257B 100B 1,298B 101B 99.03B 4,295B 17.06B 23.18B 19.9B 18.63B 32.14B 2,214B 32.23B 221B 86.24B 1,116B 87.04B 85.16B 3,693B
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
Date Price Change Volume
28/08/26 21.57 +0.37% 100
27/08/26 €21.49 -3.63% 772
26/08/26 €22.30 +0.68% 0
25/08/26 €22.15 +0.64% 0
24/08/26 €22.01 -1.30% 330
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
18.52GBP
Average target price
21.69GBP
Spread / Average Target
+17.11%

Quarterly revenue - Rate of surprise